ScreenerHero

MOLN Molecular Partners AG

NAS · US · Healthcare · Biotechnology · molecularpartners.com
3.810USD+0.79%Mkt Cap: 145.94M $P/E: —

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP03…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap145.94M USD
Enterprise Value79.91M USD
Revenue (TTM)—
Gross Profit-35.57M USD
Net Income (TTM)-61.65M USD
Revenue/Share—
Last Price3.810 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees134
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-23.11
PEG—
EV/EBITDA-1.57
EV/Revenue—
P/S—
P/B2.04
EPS (TTM)-1.71
EPS (Forward)-0.16
52W Range
3.53015% of range5.360
52W High5.360 USD
52W Low3.530 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-76.74%
ROA-60.38%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-51.26M USD
CapEx (TTM)714.00K USD
FCF Margin—
FCF Yield-18.53%
Net Debt-64.89M USD
Net Debt/EBITDA1.28
Balance Sheet
Debt/Equity0.05
Current Ratio7.27
Quick Ratio7.05
Book Value/Sh1.85 USD
Cash/Share1.77 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)10.38 USD
Upside (mean)+172.4%
Target Range3.641 USD – 16.40 USD
3.641+172.4% to mean16.40
# Analysts5
Ownership
Shares Out.38.31M
Float20.71M
Insiders0.00%
Institutions9.38%
Short Interest
Short Ratio0.2d
Short % Float0.00%
Short % Out.0.00%
Shares Short218
Short (prev mo.)187
Technical
SMA 504.166 (-8.5%)
SMA 2004.227 (-9.9%)
Beta0.69
S&P 52W Chg15.78%
Avg Vol (30d)1.42K
Avg Vol (10d)690
Technical Indicators
RSI (14)39.5
MACD-0.0925
MACD Signal-0.0469
MACD Hist.-0.0456
BB Upper4.499 USD
BB Middle4.098 USD
BB Lower3.697 USD
BB Width19.57%
ATR (14)0.1548 USD
Vol Ratio (20d)0.25x